Next Article in Journal
Neutralizing Anti-SARS-CoV-2 Antibody Titer and Reported Adverse Effects, in a Sample of Italian Nursing Home Personnel after Two Doses of the BNT162b2 Vaccine Administered Four Weeks Apart
Previous Article in Journal
Detection of Alpha- and Betacoronaviruses in Miniopterus fuliginosus and Rousettus leschenaultii, two species of Sri Lankan Bats
Article

Development of a Modular Vaccine Platform for Multimeric Antigen Display Using an Orthobunyavirus Model

1
Friedrich-Loeffler-Institut, 17493 Greifswald-Insel Riems, Germany
2
Laboratory of Virology, Wageningen Bioveterinary Research, 8221 RA Lelystad, The Netherlands
3
VTT Technical Research Centre of Finland Ltd., 02150 Espoo, Finland
4
Dyadic Netherland B.V., 6709 PA Wageningen, The Netherlands
5
Boehringer Ingelheim Animal Health, 69800 Saint-Priest, France
*
Author to whom correspondence should be addressed.
Academic Editor: Ralph A. Tripp
Vaccines 2021, 9(6), 651; https://doi.org/10.3390/vaccines9060651
Received: 5 May 2021 / Revised: 4 June 2021 / Accepted: 8 June 2021 / Published: 15 June 2021
Emerging infectious diseases represent an increasing threat to human and animal health. Therefore, safe and effective vaccines that could be available within a short time frame after an outbreak are required for adequate prevention and control. Here, we developed a robust and versatile self-assembling multimeric protein scaffold particle (MPSP) vaccine platform using lumazine synthase (LS) from Aquifex aeolicus. This scaffold allowed the presentation of peptide epitopes by genetic fusion as well as the presentation of large antigens by bacterial superglue-based conjugation to the pre-assembled particle. Using the orthobunyavirus model Schmallenberg virus (SBV) we designed MPSPs presenting major immunogens of SBV and assessed their efficacy in a mouse model as well as in cattle, a target species of SBV. All prototype vaccines conferred protection from viral challenge infection and the multivalent presentation of the selected antigens on the MPSP markedly improved their immunogenicity compared to the monomeric subunits. Even a single shot vaccination protected about 80% of mice from an otherwise lethal dose of SBV. Most importantly, the MPSPs induced a virtually sterile immunity in cattle. Altogether, LS represents a promising platform for modular and rapid vaccine design. View Full-Text
Keywords: emerging infectious disease; zoonosis; modular vaccine; epitope; lumazine synthase; Schmallenberg virus; SpyCatcher/SpyTag; C1 production host emerging infectious disease; zoonosis; modular vaccine; epitope; lumazine synthase; Schmallenberg virus; SpyCatcher/SpyTag; C1 production host
Show Figures

Figure 1

MDPI and ACS Style

Aebischer, A.; Wernike, K.; König, P.; Franzke, K.; Wichgers Schreur, P.J.; Kortekaas, J.; Vitikainen, M.; Wiebe, M.; Saloheimo, M.; Tchelet, R.; Audonnet, J.-C.; Beer, M. Development of a Modular Vaccine Platform for Multimeric Antigen Display Using an Orthobunyavirus Model. Vaccines 2021, 9, 651. https://doi.org/10.3390/vaccines9060651

AMA Style

Aebischer A, Wernike K, König P, Franzke K, Wichgers Schreur PJ, Kortekaas J, Vitikainen M, Wiebe M, Saloheimo M, Tchelet R, Audonnet J-C, Beer M. Development of a Modular Vaccine Platform for Multimeric Antigen Display Using an Orthobunyavirus Model. Vaccines. 2021; 9(6):651. https://doi.org/10.3390/vaccines9060651

Chicago/Turabian Style

Aebischer, Andrea, Kerstin Wernike, Patricia König, Kati Franzke, Paul J. Wichgers Schreur, Jeroen Kortekaas, Marika Vitikainen, Marilyn Wiebe, Markku Saloheimo, Ronen Tchelet, Jean-Christophe Audonnet, and Martin Beer. 2021. "Development of a Modular Vaccine Platform for Multimeric Antigen Display Using an Orthobunyavirus Model" Vaccines 9, no. 6: 651. https://doi.org/10.3390/vaccines9060651

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop